Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TNP-2198 + rabeprazole + amoxicillin versus bismuth quadruple therapy for primary Helicobacter pylori eradication
ChiCTR2300070540Phase 3Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifasutenizol in Helicobacter pylori infection (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Eradication rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300070540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070540.